

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Group Art Unit: 1646

HEERY et al.

Examiner: Unknown

Appln. No.: 09/423,037



Filed: February 22, 2000

FOR: INHIBITORS OF NUCLEAR PROTEIN/NUCLEAR RECEPTOR INTERACTION

Date: April 3, 2000

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Attached is Form PTO-1449 listing the enclosed documents.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Respectfully Submitted,

PILLSBURY MADISON & SUTRO LLP
Intellectual Property Group

By:

DJB:mk
1100 New York Avenue, N.W.
Ninth Floor, East Tower
Washington, D.C. 20005-3918



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 861-3027
Fax No.: (202) 822-0944

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1646
PATENT
APPLICATION

Inventor(s): HEERY et al.

Appln. No.: 09

Series Code ↑

423.037

Serial No. ↑

Group Art Unit 1646

Examiner: Unknown

Atty. Dkt. PMS 264015

M#

PHM.70228/US

Client Ref

Filed: February 22, 2000

Title: INHIBITORS OF NUCLEAR PROTEIN/NUCLEAR RECEPTOR
INTERACTION

(Our Deposit Account No. 03-3975)

(Our Order No. 9901

C#

264015

M#

Date:

April 3, 2000

Asst. Commissioner of Patents

Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. "Small Entity" statement(s) filed ☐

☐ previously
☐ herewith

(No.)

<input type="checkbox"/> previously <input type="checkbox"/> herewith	(No.)	Claims remaining after amendment	Highest number previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code
2. Total Effective Claims		56	**minus	56	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims		1	***minus	3	0	x \$78/\$39 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add						+ \$260/\$130 =	+ \$0	104/204
5. Original due Date:			<input checked="" type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached			(1 mo)		\$110/\$55 =	+ \$0		115/215
			(2 mos)		\$380/\$190 =			116/216
			(3 mos)		\$870/\$435 =			117/217
7. Enter any previous extension fee paid since above original due date and subtract						- \$0		
8. Extension Fee Attached							+ \$0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee						+ \$110/\$55 =	+ \$0	148/248
10. If IDS attached requires Official Fee, add or if Rule 97(d) Petition add						+ \$240 =	+ \$0	126
						+ \$130 =		122
11. After-Final Request Fee per rules 129(a) and 17(r)						+ \$690/345 =	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)						x \$690/345 ea =	+ \$0	149/249
13. Petition fee for							+ \$0	
14. TOTAL FEE ENCLOSED =							\$0	

15. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

16. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

17. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Madison & Sutro LLP
Intellectual Property Group

By Atty: Donald J. Bird

Sig:

Reg. No. 25323

Fax: (202) 822-0944

Tel: (202) 861-3027

1100 New York Avenue, NW

Ninth Floor

Washington, DC 20005-3918

Tel: (202) 861-3000

Atty/Sec: DJB/mk

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments